Theralink Technologies, Inc. (THER) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Golden, CO, アメリカ. 現CEOは Michael I. Ruxin.
THER を有する IPO日 2010-04-01, 16 名の正社員, に上場 Other OTC, 時価総額 $615.15K.
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. The company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. The company is headquartered in Golden, Colorado.
